17 Quotes by David Moskowitz

We sat perfectly still in the dim light as the wolf approached closer, head cocked, mouth closed, and ears semi-erect. With these signs of both curiosity and trepidation, it took a step forward and then backed off a ways, then took a few steps forward again. It lifted its nose and sniffed intently, and finally stopped at about eight feet away. For a moment all three of us were perfectly still, wondering what was going to happen next.

New management might decide to make that choice, to reinvest some of the cash from the dividend back into the company, ... meaningful growth until the end of the decade or later.

What Merck has going for them in this case is that the plaintiffs are still alive. Beyond that, these are the more relevant cases to the plaintiffs because the patients allegedly have taken the drug for more than the 18-month interval. It makes the case more compelling.

It certainly is a bellwether, especially in the New Jersey courts.

Just because we have to study history doesn't mean we can't try to relate it to the current time. Once you start talking about something they're already up on, it draws them in.

President Bush's action, although timely, may be ill advised. For the past three years, both the CDC and the WHO have steadfastly ignored our novel anti-viral approach, which has achieved over 80% treatment success in West Nile virus encephalitis and which should be equally effective against avian influenza. If the WHO had put us in touch with clinicians in Southeast Asia treating avian influenza cases as we've asked for the past three winters, we'd already know by now.

The American people saw unforgettably how federal, state, and local governments failed the people of New Orleans just three weeks ago. What the American people don't realize is how they've all been short-changed for the past three years. Minorities are much more affected by kidney failure than whites. There's a dialysis boom on Indian reservations.

Merck has a precedent of announcing head count reductions and then coming back to the table and cutting even further.

We believe this decision is only worth $1 to $2 in upside to Merck, as this case was known to be relatively weak,